



April 6, 2016

PerkinElmer to Showcase Cancer Research Technologies at AACR Annual Meeting 2016

WHAT: [PerkinElmer, Inc.](#), a global leader focused on improving the health and safety of people and the environment, today announced that it will display its wide range of innovative solutions for precision oncology drug discovery research at the 2016 American Association for Cancer Research (AACR) Annual Meeting.

"PerkinElmer's extensive portfolio of technologies supports cancer research and helps scientists develop breakthrough therapeutic treatments for better health outcomes," said Brian Kim, President, Life Sciences & Technology, PerkinElmer. "Our reagents, imaging and detection instrumentation and software for in vitro, ex vivo and in vivo models, will enable these researchers to make faster, more targeted discoveries."

WHEN: April 17-20, 2016

WHERE: Ernest N. Morial Convention Center, New Orleans, Louisiana (Booth#1312-1313)

ON DISPLAY: PerkinElmer will showcase the following offerings at AACR 2016:

[Vectra® 3 Automated Quantitative Pathology Imaging System](#): provides a high-throughput system for phenotyping and quantification of biomarker expression levels in tissue, all in a familiar digital workflow. This system is part of PerkinElmer's Phenoptics™ workflow solution for quantitative pathology research, which enables exploration of the interaction between tumors and immune cells to obtain a deeper understanding of disease mechanisms.

[Opal® Multiplex IHC Cancer Immunology Panels](#): combines optimized sets of antibodies and detection reagents with verified protocols to provide a direct route to biologically relevant results in the tumor microenvironment. These new research panels are also part of PerkinElmer's Phenoptics™ workflow solution.

[IVIS® Spectrum CT In Vivo Imaging System](#): helps researchers achieve simultaneous molecular and anatomical longitudinal studies for essential insight into complex biological systems in small animal models. The system contains a comprehensive suite of fluorescent and bioluminescent imaging agents and uses integrated optical and microCT technology, 3D optical tomography and sensitive detection technology.

[G8 PET/CT Imaging system and ImmunoPET radionuclides: 89Zr and 124I](#): an ultra-sensitive and fast multimodal preclinical PET/CT imaging system in a benchtop format, enabling researchers to image trace amounts of probe (about 10x lower dose than conventional scanners), reducing barriers to PET imaging, exposure to subjects and researchers, and overall costs. With integrated anesthesia, intuitive workflows, a user-friendly software interface and radionuclides, PerkinElmer can design a complete PET solution for oncology and drug discovery applications.

[Quantum GX microCT imaging system](#): helps scientists obtain a better understanding of disease and its progression through combined high-speed, low-dose x-ray, and high-resolution microCT imaging. This small animal multispecies imaging system enables true longitudinal imaging across a broad-range of applications.

▮ **Advanced microCT Bone Analysis Software**: designed to remove manual

manipulations that often result in higher variance between users. This automated workflow-based software outputs segmented 3D images with quantitative analytical data in a user-friendly interface, which helps researchers obtain more accurate results and increase analysis throughput.

[Operetta® CLS™ High-Content Analysis System](#): facilitates the identification of subtle phenotypic changes and provides deep biological information from everyday assays to help enable innovative applications for cancer research and drug discovery. This system combines technologies to deliver speed, sensitivity and resolution.

[EnSight™ Multimode Plate Reader](#): the first benchtop system to offer well imaging, label-free and labelled detection technologies, enabling researchers compare and combine results from orthogonal assays using a range of technologies to make new findings on a single, flexible and upgradeable system.

[LabChip® GX Touch System](#): streamlines multiple, manual steps of slab gel electrophoresis to provide rapid, reproducible data with the highest sensitivity, even at the lowest sample concentrations.

[JANUS® G3 NGS Express Workstation](#): performs library prep for benchtop sequencers, enabling preparation of up to 24 libraries and supporting the applications of multiple sequencers.

[LANCE® TR-FRET Reagents](#): offer a simple, highly-sensitive, and highly-reproducible platform for detection, quantitation and screening in microplate format. From oncology biomarker detection assays to kinase and epigenetic assays, the LANCE® and LANCE Ultra TR-FRET technologies offer researchers the fastest time to results and the brightest signal with no wash or separation steps.

[Alpha SureFire® Reagents](#): no-wash cellular kinase assays available in multiple formats, utilizing PerkinElmer's exclusive bead-based Alpha technology in a sandwich immunoassay format for detection of phosphorylated proteins in the cell. These assays are a quantitative alternative to Western Blotting in an automation-friendly, easy to miniaturize format and are able to detect endogenous, as well as recombinant, proteins.

POSTERS:

PerkinElmer will also feature the following scientific posters:

"Understanding Immune Phenotypes and Their Spatial Relationships To Breast Adenocarcinoma in FFPE Tissues"

Adoptive Cell Therapy, Immune Checkpoints, and Vaccines
Monday, April 18, 1:00 PM - 5:00 PM
Convention Center, Halls G-J, Poster Section 21

"Simultaneous Fluorescence Tomographic Imaging of Efficacy and Toxicity Following Acute 5-FU Treatment of HT-29 Tumor Xenografts"

Late-Breaking Research: Tumor Biology 2e
Monday, April 18, 1:00 PM - 5:00 PM
Section 11, Poster Board Number 15

"Multispectral open-air fluorescence-guided imaging and detection of tumors using a hands-free translational platform with liquid crystal tunable filters (LCTF)"

Molecular and Cellular Imaging of Cancer 2
Tuesday, April 19, 1:00 PM - 5:00 PM
Section 34, Poster Board Number 24

PRESENTATION:

Pre-existing Immunity and Treatment Outcome with Anti-PD1 in Melanoma

Monday, April 18, 3:00 to 4:00 P.M., AACR Exhibitor Spotlight Theater

Presenters:

Paul Tumeah, MD, Assistant Professor, UCLA Medical Center, Dept. of Medicine Clifford Hoyt, Oncology Fellow, PerkinElmer

Abstract:

Therapies that block the PD-1/PD-L1 axis have shown significant clinical activity in melanoma and other cancers. Recent evidence has shown that pre-existing CD8 T cells infiltrates at the invasive tumor margin of metastatic melanoma are associated with the presence of the PD-1/PD-L1 immune axis and may predict response to therapy. We examined the relationship between site of metastatic disease, local immune response, and treatment outcome in patients with advanced melanoma.

MORE:

For more information on PerkinElmer's presence at AACR 2016, please visit:

www.perkinelmer.com/aacr

Follow us on Twitter @PKILifeScience and join the conversation around AACR.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately \$2.3 billion in 2015, has approximately 8,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

Media Contact:

Alison Cizowski

+1 617-399-4914

perkinelmerlss@apcoworldwide.com